Citius Pharmaceuticals Inc vs Alphabet Inc Class A — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Alphabet Inc Class A trades at $343.54 (market cap $4.20T). The key difference: Alphabet Inc Class A is far larger — about 209895.1× Citius Pharmaceuticals Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GOOGL | |
|---|---|---|
Market Cap | $20.01M | $4.20T |
Sector | Health | Media |
52-Week High | $1.82 | $402.62 |
52-Week Low | $0.48 | $199.32 |
Enterprise Value | $16.23M | $4.09T |
Dividend Yield | — | 0.26% |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
Alphabet (GOOGL) trades at $344.00, down 3.78% on the day, with technical indicators showing bearish momentum below key resistance at $347. Fundamentally, the company demonstrates strong profitability with 54.77% net income margin and consistent earnings beats, though valuation multiples remain elevated with P/E at 17.25. Recent developments include YouTube subscription price increases and continued AI infrastructure investments.
The stock presents a compelling long-term opportunity given strong analyst consensus (85% buy ratings) and $426.28 price target, representing 24% upside. Key risks include antitrust scrutiny and tech sector rotation pressures, but Alphabet's AI leadership and diversified revenue streams support growth prospects despite near-term volatility.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →